News | Nuclear Imaging | July 27, 2022

House-passed Appropriations Bills Include Key Measures to Improve Nuclear Medicine Patient Safety 

House-passed Appropriations Bills Include Key Measures to Improve Nuclear Medicine Patient Safety

July 27, 2022 — Patients for Safer Nuclear Medicine, a coalition of 29 patient advocacy organizations representing thousands of patients, along with more than 600 concerned US citizens today praised the House of Representatives for passing two appropriations bills that include important language calling on federal agencies to improve patient safety in nuclear medicine

Radioactive drug misadministrations caused by human error, inadequate training, lack of quality procedures, and that exceed defined radiation dose thresholds are currently reportable to NRC. Extravasations occur when radioactive drugs used in nuclear medicine procedures are inadvertently injected into the patient’s tissue instead of a vein.  Despite potential consequence to patient safety, even the most severe extravasations are exempted from NRC reporting requirements due to a 42 year-old loophole in NRC policy. 

Appropriations bills passed by the House of Representatives last week call on the U.S. Nuclear Regulatory Commission (NRC) to update its internal rules on reporting significant unintended irradiation, and call on the Veterans Health Administration to monitor injection quality and report significant extravasations. 

“30 million administrations of radioactive drugs occur every year in the US, but NRC has excluded extravasations from reporting, even if they cause radiation doses hundreds of times higher than other reportable events,” says Patients for Safer Nuclear Medicine spokesperson Mary Ajango. “Patients need to know if their care is affected. The worst approach is to do nothing and wait for patients to be injured.” 

The House-passed package of Appropriations bills included the following language regarding NRC: Re-Evaluation of Nuclear Medicine Event Reporting —The Committee is closely monitoring the Commission’s reconsideration of its policy related to significant extravasations and medical event reporting. Evidence shows that nuclear medicine extravasations may be avoidable and that some extravasations may exceed medical event reporting provided in 10 C.F.R. Part 35 Subpart M. These events may harm patients through unintended radiation exposure, compromised imaging that negatively affects care, additional interventional procedures, and repeated imaging procedures. The Committee continues to encourage the Commission to consider the inclusion of significant extravasations in medical event reporting to improve safety, quality, and transparency for patients, treating physicians, and the Commission itself. 

The package also included the following language regarding the VA: 

Nuclear Medicine Quality Improvements —The Committee is aware of the consequence of extravasations in nuclear medicine procedures, and understands that the Nuclear Regulatory Commission and Centers for Medicare and Medicaid Services are considering regulatory actions to improve nuclear medicine injection quality. The Committee continues to encourage VA to monitor injection quality, as well as image extravasations, perform dosimetry and notify patients when they occur, and urges the Department to adopt any new regulatory requirements. 

For more information: https://www.unchealthcare.org/


Related Content

News | FDA

March 1, 2024 — Varian, a Siemens Healthineers company, announced that it has received 510(k) clearance from the U.S ...

Time March 01, 2024
arrow
News | Breast Imaging

February 22, 2024 — The FAST-Forward randomized trial from the UK found that ultrahypofractionated whole breast ...

Time February 22, 2024
arrow
News | Radiation Oncology

February 22, 2024 — The National Institutes of Health has launched a clinical trials network to evaluate emerging ...

Time February 22, 2024
arrow
News | Radiopharmaceuticals and Tracers

February 21, 2024 — Blue Earth Therapeutics, a Bracco company and emerging leader in the development of innovative next ...

Time February 21, 2024
arrow
News | Radiopharmaceuticals and Tracers

February 14, 2024 — PanTera, the Belgian joint venture created by IBA and SCK CEN to secure large-scale production of ...

Time February 14, 2024
arrow
News | Radiation Oncology

February 14, 2024 — Accuray Incorporated announced that the team at Quebec’s Montérégie Integrated Cancer Center, part ...

Time February 14, 2024
arrow
News | Radiation Oncology

February 12, 2024 — Radformation, a global pioneer in radiation oncology software solutions, is pleased to announce its ...

Time February 12, 2024
arrow
News | Quality Assurance (QA)

February 12, 2024 — IBA, a world leader in particle accelerator technology and a world-leading provider of dosimetry and ...

Time February 12, 2024
arrow
News | PET Imaging

February 9, 2024 — A novel PET imaging technique can noninvasively detect active inflammation in the body before ...

Time February 09, 2024
arrow
News | Radiation Therapy

February 8, 2024 — RaySearch Laboratories AB announced that The Royal Marsden NHS Foundation Trust, a specialist cancer ...

Time February 08, 2024
arrow
Subscribe Now